{"id":3918,"date":"2016-05-18T13:45:26","date_gmt":"2016-05-18T13:45:26","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/"},"modified":"2016-05-18T13:45:26","modified_gmt":"2016-05-18T13:45:26","slug":"fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/","title":{"rendered":"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong><\/strong><\/span><\/p>\n<p><span><strong>Nyemissionen i Nanexa AB (publ) avslutades i f\u00f6rra veckan och tecknades till 21,0 MSEK, motsvarande en teckningsgrad om 103,4 procent.\u00a0 I emissionen tecknades 13,3 MSEK med st\u00f6d av teckningsr\u00e4tter och 7,0 MSEK utan st\u00f6d av teckningsr\u00e4tter. Bolaget tillf\u00f6rs nu 20,3 MSEK f\u00f6re transaktionskostnader. <\/strong><\/span><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p><span>Totalt emitteras 2\u00a0536 644 nya aktier i emissionen och det totala antalet aktier efter emissionen uppg\u00e5r till 7\u00a0609 933 stycken. Bolaget tillf\u00f6rs d\u00e4rmed 20,3 MSEK f\u00f6re emissionskostnader efter att full betalning skett. Emissionskostnaderna ber\u00e4knas uppg\u00e5 till cirka 2,0 MSEK, varav kostnaden f\u00f6r emissionsgarantin f\u00f6rv\u00e4ntas uppg\u00e5 till 0,6 MSEK. Pengarna ska anv\u00e4ndas till att finansiera och accelerera fortsatta studier med bolagets unika, nanobaserade drug delivery-system Pharma Shell\u00ae. I och med emissionen \u00f6kar bolagets aktiekapital med 328 296 kronor och uppg\u00e5r till 984\u00a0888 kronor efter emissionen. <\/span><\/p>\n<\/p>\n<p><span>VD David Westberg kommenterar:<\/span><\/p>\n<\/p>\n<p><span>Jag och styrelsen \u00e4r v\u00e4ldigt n\u00f6jda med utfallet av emissionen. Det g\u00f6r att vi nu kan forts\u00e4tta den utstakade v\u00e4gen mot kommersiella avtal med relevanta l\u00e4kemedelsf\u00f6retag. Jag vill passa p\u00e5 att tacka gamla aktie\u00e4gare f\u00f6r fortsatt f\u00f6rtroende och v\u00e4lkomna nya aktie\u00e4gare till Nanexa. <\/span><\/p>\n<\/p>\n<p><span>F\u00f6r mer information kontakta:<\/span><\/p>\n<\/p>\n<p><span>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<\/span><\/p>\n<\/p>\n<p><span>?Telefon: 0709 -42 83 03?<\/span><\/p>\n<\/p>\n<p><span>E-post:\u00a0david.westberg@nanexa.se<\/span><\/p>\n<\/p>\n<p><span><a href=\"http:\/\/www.nanexa.se\/\" rel=\"nofollow\">www.nanexa.se<\/a><\/span><\/p>\n<\/p>\n<p><span>Om Nanexa AB (publ)<\/span><\/p>\n<\/p>\n<p><span>Nanexa AB \u00e4r ett h\u00f6gteknologiskt forskningsf\u00f6retag som utvecklar och marknadsf\u00f6r produkter inom nanoteknologi. Bolagets fokus ligger p\u00e5 PharmaShell\u00ae som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal omr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae har Nanexa samarbetsavtal med bland andra AstraZeneca, Uppsala universitet och Karolinska Institutet.<\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/aktietorget.blob.core.windows.net\/press\/news\/nanexa\/78553\/517489.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nyemissionen i Nanexa AB (publ) avslutades i f\u00f6rra veckan och tecknades till 21,0 MSEK, motsvarande en teckningsgrad om 103,4 procent.  I emissionen tecknades 13,3 MSEK med st\u00f6d av teckningsr\u00e4tter och 7,0 MSEK utan st\u00f6d av teckningsr\u00e4tter. Bolaget tillf\u00f6rs nu 20,3 MSEK f\u00f6re transaktionskostnader.<\/p>\n","protected":false},"template":"","class_list":["post-3918","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ca_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ca-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nyemissionen i Nanexa AB (publ) avslutades i f\u00f6rra veckan och tecknades till 21,0 MSEK, motsvarande en teckningsgrad om 103,4 procent. I emissionen tecknades 13,3 MSEK med st\u00f6d av teckningsr\u00e4tter och 7,0 MSEK utan st\u00f6d av teckningsr\u00e4tter. Bolaget tillf\u00f6rs nu 20,3 MSEK f\u00f6re transaktionskostnader.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\\\/\",\"name\":\"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2016-05-18T13:45:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/","og_locale":"sv_SE","og_type":"article","og_title":"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae - Nanexa AB","og_description":"Nyemissionen i Nanexa AB (publ) avslutades i f\u00f6rra veckan och tecknades till 21,0 MSEK, motsvarande en teckningsgrad om 103,4 procent. I emissionen tecknades 13,3 MSEK med st\u00f6d av teckningsr\u00e4tter och 7,0 MSEK utan st\u00f6d av teckningsr\u00e4tter. Bolaget tillf\u00f6rs nu 20,3 MSEK f\u00f6re transaktionskostnader.","og_url":"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/","url":"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/","name":"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2016-05-18T13:45:26+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/fulltecknad-emission-finansierar-fortsatt-utveckling-av-pharmashell\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Fulltecknad emission finansierar fortsatt utveckling av PharmaShell\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3918","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3918"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}